Business
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026
PORTLAND, Maine, May 14, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops and markets products to improve calf health and productivity, today announced its unaudited financial results for the quarter ended March 31, 2026. Management’s Discussion: “Today we are reporting net income of $1.9 million for the first quarter of 2026, which is an increase of $0.5 million compared to the first quarter of 2025,” co
About this update from Immucell Corporation
[{"type":"image","alt":"ImmuCell Corporation","displaySize":"","headline":null,"caption":"ImmuCell Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":36,"url":"https://media.zenfs.com/en/globenewswire.com/444055d59bf7cb6f681f3be8a2dd02bc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/k4qXurrdDfdjDQTAoB.o8g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUw/https://media.zenfs.com/en/globenewswire.com/444055d59bf7cb6f681f3be8a2dd02bc","width":300,"height":36},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/k4qXurrdDfdjDQTAoB.o8g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUw/https://media.zenfs.com/en/globenewswire.com/444055d59bf7cb6f681f3be8a2dd02bc","width":300,"height":36}},"lazy":false},{"type":"text","content":"PORTLAND, Maine, May 14, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops and markets products to improve calf health and productivity, today announced its unaudited financial results for the quarter ended March 31, 2026.","length":313,"tagName":"p"},{"type":"text","content":"Management’s Discussion:","length":24,"tagName":"p"},{"type":"text","content":"“Today we are reporting net income of $1.9 million for the first quarter of 2026, which is an increase of $0.5 million compared to the first quarter of 2025,” commented Timothy C. Fiori, Chief Financial Officer of ImmuCell. “These results were driven by 28.4% growth in product sales to $10.4 million and an expansion of gross margins to 45.0% that reflects higher volumes, manufacturing efficiencies, and price realization. ImmuCell generated $3.4 million free cash flow in the first quarter of 2026, improving its cash position to $6.8 million as of March 31, 2026, while maintaining a healthy level of inventory on hand after meeting peak seasonal demand these past two quarters.”","length":683,"tagName":"p"},{"type":"text","content":"“We had a record revenue quarter driven by high seasonal demand from the cow-calf segment and an increase in our market share in the U.S. scours biologicals market by approximately 3% of animals treated,” explained Bobbi Brockmann, Senior Vice President of Sales and Marketing at ImmuCell. “As we move past our peak season, revenue traditionally moderates mid-year, and year over year growth rates will be impacted by the large backorder cleared...